Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

In an effort to offset declining COVID-19 product sales, Pfizer embarked on an aggressive acquisition strategy, purchasing Seagen, Global Blood Therapeutics, and Biohaven. While the Seagen ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE), have recently been scrutinized after President Trump’s executive order instructing drug manufacturers to reduce medicine prices to align with ...

The advisory committee, which met after the agency rolled out new vaccine guidelines, said companies should tailor their ...

Job cuts at home-grown pharma companies like Arvinas and RallyBio and federal policies challenge CT biotech 'ecosystem' that ...

No date has yet been fixed for the AdCom meeting. BHVN, a spinout of Biohaven Pharmaceutical when Pfizer (PFE) acquired the migraine therapy maker in 2022, noted that the FDA did not raise any ...

If it wins approval, troriluzole would represent Biohaven’s first greenlit product since it spun out from its migraine business following a $11.6bn acquisition from Pfizer back in 2022.

In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...

Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi's M42 alongside strategic partnership Close of $76m Series B-1 tranche follows recent announcement of groundbreaking ...

Fremanezumab reduced migraine attacks and depression symptoms in migraine patients with major depressive disorder. Migraine and major depression are frequently comorbid. Fremanezumab selectively ...

MÁLAGA, Spain — Semaglutide (Wegovy) is associated with a 41% reduction in the risk for major adverse cardiovascular events (MACEs) within 6 months of initiation — well before patients ...